0001213900-26-045668
SEC filingAlpha Cognition Inc. appointed Bethany Sensenig, experienced biotech CFO, as a new director on April 15, 2026, with standard non-employee compensation including initial equity grants.
The appointment of Bethany Sensenig strengthens the Board with her extensive finance and operations leadership in biotechnology. Her track record includes driving growth and sales at Radius Health, interim CEO duties at 9 Meters Biopharma, and strategic financing at Minovia Therapeutics, plus significant P&L oversight at Biogen across global markets. Current board roles at Supernus Pharmaceuticals and KalVista Pharmaceuticals add relevant public company governance experience. The standard compensation package, including an initial equity grant aligned with the non-employee director policy, incentivizes long-term alignment without unusual terms or conflicts.